Related Experiment Video
Updated: Aug 11, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
Published on: February 24, 2026
Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients
D Ben Smail1, A Peskine, N Roche
1Service de Médecine Physique et Readaptation, Hôpital R. Poincaré, 104 Bd R. Poincaré, 92380 Garches, France. djamel.bensmail@rpc.aphp.fr
Abstract:
We conducted a retrospective study of the case files of 64 multiple sclerosis (MS) patients presenting severe spasticity, who had received intrathecal (IT) baclofen test injections between 1992 and 2004 in a rehabilitation unit. In almost all cases of our series, IT baclofen was proposed to patients who were no longer able to walk. IT baclofen is a safe and effective treatment to reduce spasticity in MS patients. Despite an advanced stage of the disease at the time of pump placement, the complication rate was low and the efficacy of this treatment was maintained over time.
More Related Videos
Related Concept Videos
Skeletal Muscle Relaxants: Therapeutic Uses
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Local Anesthetics: Clinical Application as Spinal Anesthesia
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...

